These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. Delgado MG; Gracia-Sancho J; Marrone G; Rodríguez-Vilarrupla A; Deulofeu R; Abraldes JG; Bosch J; García-Pagán JC Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(7):G496-502. PubMed ID: 23886859 [TBL] [Abstract][Full Text] [Related]
27. [The protection of myocardial ischemia--reperfusion injury]. Miura M; Fujiwara Y Nihon Rinsho; 2003 Apr; 61 Suppl 4():667-74. PubMed ID: 12735048 [No Abstract] [Full Text] [Related]
28. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Albillos A; Lledó JL; Rossi I; Pérez-Páramo M; Tabuenca MJ; Bañares R; Iborra J; Garrido A; Escartín P; Bosch J Gastroenterology; 1995 Oct; 109(4):1257-65. PubMed ID: 7557093 [TBL] [Abstract][Full Text] [Related]
29. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model. Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654 [TBL] [Abstract][Full Text] [Related]
35. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Wiest R; Groszmann RJ Semin Liver Dis; 1999; 19(4):411-26. PubMed ID: 10643626 [TBL] [Abstract][Full Text] [Related]
36. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats. Van de Casteele M; Hösli M; Sägesser H; Reichen J J Hepatol; 1999 Aug; 31(2):300-5. PubMed ID: 10453944 [TBL] [Abstract][Full Text] [Related]
37. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Grace JA; Herath CB; Mak KY; Burrell LM; Angus PW Clin Sci (Lond); 2012 Aug; 123(4):225-39. PubMed ID: 22548407 [TBL] [Abstract][Full Text] [Related]
38. Current concepts on the pathophysiology of portal hypertension. Rodríguez-Vilarrupla A; Fernández M; Bosch J; García-Pagán JC Ann Hepatol; 2007; 6(1):28-36. PubMed ID: 17297426 [TBL] [Abstract][Full Text] [Related]
39. Vascular Targets for the Treatment of Portal Hypertension. Brusilovskaya K; Königshofer P; Schwabl P; Reiberger T Semin Liver Dis; 2019 Nov; 39(4):483-501. PubMed ID: 31315135 [TBL] [Abstract][Full Text] [Related]
40. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. Fiorucci S; Antonelli E; Brancaleone V; Sanpaolo L; Orlandi S; Distrutti E; Acuto G; Clerici C; Baldoni M; Del Soldato P; Morelli A J Hepatol; 2003 Dec; 39(6):932-9. PubMed ID: 14642608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]